Proprietary GRIT platform technology to engineer Tregs to overcome challenges associated with previous generations of Treg cell therapies
Extracellular vesicle platform developing novel therapeutics to regenerate tissue in autoimmune diseases
First-in-class therapeutic targeting novel circulating factor
First-in-class therapeutics utilising cell depletion approaches for autoimmune and immune mediated inflammatory disorders
First-in-class therapeutic targeting novel metabolite transport